Voluven® 6%

HES 130/0.4 in 0.9% sodium chloride solution - The latest generation of starches.

Features

Voluven® 

  • 6% hydroxyethyl starch 130/0.4 in 0,9% sodium chloride solution
  • Derived from waxy maize starch (potato starch is not bioequivalent*)
  • Iso-oncotic solution – suitable for volume replacement
  • Provides both initial and medium-term volume effects (4-6 h)
  • Millions of patients worldwide treated since 1999
  • Supported by extensive clinical evidence

* Lehmann et al., Drugs R D 2007; 8(4): 229-240

Please refer to the nationally registered and approved SmPC.

The signs/names marked with ® are registered trademarks of the Fresenius Group in selected countries.

Indications

Voluven® is indicated for the treatment and prophylaxis of hypovolaemia in adults and children. It is not a substitute for red blood cells or coagulation factors in plasma.

Hypovolaemia

  • Hypovolaemia is associated with disturbances in macro- and microcirculation.

Macro- and microcirculation disturbances give rise to diminished organ blood flow and decreased oxygen supply to various organs, and finally to functional organ failure.

Please refer to the nationally registered and approved SmPC.

The signs/names marked with ® are registered trademarks of the Fresenius Group in selected countries.

Product Information

​Please note that this product may not be available in all countries due to different registration status. Additionally, approved indications, contraindications, side effects, warnings and all other product characteristics may differ between countries.

If you require any information, please contact your local organization.

The Important Safety Guidance might differ in your respective country depending on decision of your local regulatory authority. To receive the local Important Safety Guidance in addition please visit the respective country homepage or contact the respective local Fresenius Kabi organization.

Please refer to the nationally registered and approved SmPC. ​